The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationGenetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Roy, R., Chun, J., & Powell, S. N. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3181 · Cited by 1,469
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,051
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Self-citationRisch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
Breast-Cancer Risk in Families with Mutations in PALB2
Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., De Leeneer, K., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 851
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 691
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Breast Cancer Susceptibility Collaboration (UK), Loveday, C., Turnbull, C., Ramsay, E., Hughes, D., Ruark, E., Frankum, J. R., Bowden, G., Kalmyrzaev, B., Warren-Perry, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.893 · Cited by 534
Konstantinopoulos, P. A., Spentzos, D., Karlan, B. Y., Taniguchi, T., Fountzilas, E., Francoeur, N., Levine, D. A., & Cannistra, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5719 · Cited by 483
Zhang, S., Royer, R., Li, S., McLaughlin, J. R., Rosen, B., Risch, H. A., Fan, I., Bradley, L., Shaw, P. A., & Narod, S. A. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.01.020 · Cited by 423
EMSY Links the BRCA2 Pathway to Sporadic Breast and Ovarian Cancer
Hughes-Davies, L., Huntsman, D., Ruas, M., Fuks, F., Bye, J., Chin, S.-F., Milner, J., Brown, L. A., Hsu, F., Gilks, B., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00930-9 · Cited by 421
Mutations in BRIP1 confer high risk of ovarian cancer
Rafnar, T., Gudbjartsson, D. F., Sulem, P., Jonasdottir, A., Sigurdsson, A., Jonasdottir, A., Besenbacher, S., Lundin, P., Stacey, S. N., Gudmundsson, J., et al. (2011) · Nature Genetics · doi:10.1038/ng.955 · Cited by 406
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
Schwarz, R. F., Ng, C. K. Y., Cooke, S. L., Newman, S., Temple, J., Piskorz, A. M., Gale, D., Sayal, K., Murtaza, M., Baldwin, P. J., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001789 · Cited by 400
Hennessy, B. T. J., Timms, K. M., Carey, M. S., Gutin, A., Meyer, L. A., Flake, D. D., Abkevich, V., Potter, J., Pruss, D., Glenn, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2997 · Cited by 374
Somatic mutations in the BRCA1 gene in sporadic ovarian tumours
Merajver, S. D., Pham, T. M., Caduff, R. F., Chen, M., Poy, E. L., Cooney, K. A., Weber, B. L., Collins, F. S., Johnston, C., & Frank, T. S. (1995) · Nature Genetics · doi:10.1038/ng0495-439 · Cited by 372
Banerjee, S., & Kaye, S. B. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2243 · Cited by 357
Self-citationWatkins, J. A., Irshad, S., Grigoriadis, A., & Tutt, A. N. (2014) · Breast Cancer Research · doi:10.1186/bcr3670 · Cited by 327
Cancer risks among BRCA1 and BRCA2 mutation carriers
Levy-Lahad, E., & Friedman, E. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603535 · Cited by 327
Graeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 327
BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
Baldwin, R. L., Nemeth, E., Tran, H., Shvartsman, H. S., Cass, I. A., Narod, S. A., & Karlan, B. Y. (2000) · PubMed · Cited by 324
Mukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomsky, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 270
Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Redon, C. E., Nakamura, A. J., Zhang, Y.-W., Ji, J. (., Bonner, W. M., Kinders, R. J., Parchment, R. E., Doroshow, J. H., & Pommier, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0523 · Cited by 255
Germline RAD51C mutations confer susceptibility to ovarian cancer
Breast Cancer Susceptibility Collaboration (BCSC) (UK), Loveday, C., Turnbull, C., Ruark, E., Xicola, R. M. M., Ramsay, E., Hughes, D., Warren-Perry, M., Snape, K., Eccles, D., et al. (2012) · Nature Genetics · doi:10.1038/ng.2224 · Cited by 252
Ovarian carcinoma pathology and genetics: recent advances
Gilks, C. B., & Prat, J. (2009) · Human Pathology · doi:10.1016/j.humpath.2009.04.017 · Cited by 249
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination–Defective Cells
Gottipati, P., Vischioni, B., Schultz, N., Solomons, J., Bryant, H. E., Djureinovic, T., Issaeva, N., Sleeth, K., Sharma, R. A., & Helleday, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4716 · Cited by 227
The CHEK2 gene and inherited breast cancer susceptibility
Nevanlinna, H., & Bartek, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209877 · Cited by 219
BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
Ferrone, C. R., Levine, D. A., Tang, L. H., Allen, P. J., Jarnagin, W., Brennan, M. F., Offit, K., & Robson, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5546 · Cited by 206
Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2 and RAD51C Status
Cunningham, J. M., Cicek, M. S., Larson, N. B., Davila, J. I., Wang, C., Larson, M. C., Song, H., Dicks, E., Harrington, P. A., Wick, M. J., et al. (2014) · Scientific Reports · doi:10.1038/srep04026 · Cited by 152
Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
Lupo, B., & Trusolino, L. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.004 · Cited by 148
BRCA1 promoter methylation predicts adverse ovarian cancer prognosis
Chiang, J. W., Karlan, B. Y., Cass, L., & Baldwin, R. L. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.10.034 · Cited by 125
Predictive biomarkers for cancer therapy with PARP inhibitors
Michels, J., Vitale, I., Saparbaev, M. K., Castedo, M., & Kroemer, G. (2013) · Oncogene · doi:10.1038/onc.2013.352 · Cited by 124
Willers, H., Taghian, A. G., Luo, C., Treszezamsky, A. D., Sgroi, D. C., & Powell, S. N. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0149 · Cited by 117
Making the best of PARP inhibitors in ovarian cancer
Banerjee, S. N., Kaye, S. B., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.116 · Cited by 107
Self-citationSøgaard, M., Kjær, S. K., Cox, M. J., Woźniak, E. L., Høgdall, E. V. S., Høgdall, C. K., Blaakær, J., Jacobs, I. J., Gayther, S. A., & Ramus, S. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4806 · Cited by 105
BRCAness: Finding the Achilles Heel in Ovarian Cancer
Rigakos, G., & Razis, E. D. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0028 · Cited by 102
George, J., Alsop, K., Etemadmoghadam, D., Hondow, H., Mikeska, T., Dobrovic, A., DeFazio, A., Chenevix‐Trench, G., Smyth, G. K., Levine, D. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0066 · Cited by 98
McNeish, I. A., Oza, A. M., Coleman, R. L., Scott, C. L., Konecny, G. E., Tinker, A. V., O’Malley, D. M., Brenton, J. D., Kristeleit, R. S., Bell‐McGuinn, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5508 · Cited by 93
Gourley, C., Michie, C. O., Roxburgh, P., Yap, T. A., Harden, S., Paul, J., Ragupathy, K., Todd, R., Petty, R., Reed, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1082 · Cited by 88
Self-citationBrown, L. A., Irving, J., Parker, R. L., Kim, H., Press, J. Z., Longacre, T. A., Chia, S., Magliocco, A. M., Makretsov, N. A., Gilks, C. B., et al. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.026 · Cited by 83
Hoeijmakers, J. H. J. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.05.002 · Cited by 70
Piek, J. M. J., Torrenga, B., Hermsen, B. B. J., Verheijen, R. H. M., Zweemer, R. P., Gille, J. J. P., Kenemans, P., van Diest, P. J., & Menko, F. H. (2003) · Familial Cancer · doi:10.1023/a:1025700807451 · Cited by 66
BRCAness Profile of Sporadic Ovarian Cancer Predicts Disease Recurrence
Wysham, W. Z., Mhawech-Fauceglia, P. Y., Li, H., Hays, L. E., Syriac, S., Skrepnik, T., Wright, J., Pande, N. T., Hoatlin, M. E., & Pejovic, T. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030042 · Cited by 61
Zhang, S., Yuan, Y., & Hao, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113169 · Cited by 44
Biomarkers of PARP inhibitor sensitivity
Turner, N. C., & Ashworth, A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1375-8 · Cited by 32
Tan, D. S. P., Yap, T. A., Hutka, M., Roxburgh, P., Ang, J. E., Banerjee, S. N., Grzybowska, E. A., Gourley, C., Gore, M. E., & Kaye, S. B. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.016 · Cited by 28
Self-citationKristeleit, R. S., Swisher, E. M., Oza, A. M., Coleman, R. L., Scott, C. G., Konecny, G. E., Tinker, A. V., O’Malley, D. M., Brenton, J. D., Bell‐McGuinn, K. M., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(15)30050-2 · Cited by 23
Lin, K., Sun, J. X., Maloney, L., Goble, S. M., Oza, A. M., Coleman, R., Scott, C. L., Robillard, L., Mann, E., Isaacson, J., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31469-1 · Cited by 15
Swisher, E., Brenton, J. D., Kaufmann, S., Oza, A. M., Coleman, R. L., O’Malley, D. M., Konecny, G. E., Ma, L., Harrell, M. I., Visscher, D. W., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70341-7 · Cited by 10
Yates, M. S., Timms, K. M., Daniels, M. S., Batte, B. A. L., Ring, K. L., Neff, C. D., Potter, J., Chau, S., Chen, J., Williams, D., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu338.10 · Cited by 6
Cited by
CA125 and Ovarian Cancer: A Comprehensive Review
Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2020) · Cancers · doi:10.3390/cancers12123730 · Cited by 602
Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types
Heeke, A. L., Pishvaian, M. J., Lynce, F., Xiu, J., Brody, J. R., Chen, W.-J., Baker, T. M., Marshall, J. L., & Isaacs, C. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00286 · Cited by 467
Ovarian Cancer Immunotherapy and Personalized Medicine
Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126532 · Cited by 372
Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)
Yang, L., Xie, H.-J., Li, Y.-Y., Wang, X., Liu, X.-X., & Mai, J. (2022) · Oncology Reports · doi:10.3892/or.2022.8293 · Cited by 304
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
Metadata
- Authors
- Moschetta, M., George, A., Kaye, S. B., & Banerjee, S.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-08
- Volume
- 27
- Issue
- 8
- Pages
- 1449-1455
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2332185934
- Cited by
- 292
- References
- 66
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.